NASDAQ$RAPT
RAPT Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
RAPT Therapeutics reported financial results, highlighting positive topline results from Phase 1b clinical trial of RPT193 in atopic dermatitis and a public offering that bolstered cash position.
RAPT Therapeutics reported a net loss of $16.1 million for the second quarter of 2021, compared to a net loss of $12.4 million for the same period in 2020. The company highlighted positive results from a Phase 1b clinical trial and the closing of a public offering that increased their cash reserves.
- Announced positive topline results from Phase 1b clinical trial of RPT193 in atopic dermatitis.
- Closed an underwritten public offering with net proceeds of $134.6 million.
- Demonstrated early proof-of-concept for RPT193 and FLX475 in atopic dermatitis and cancer, respectively.
- Well positioned to advance product development efforts and report additional data.
Headline financials
Revenue & EPS history
RAPT · Revenue · Quarterly
$869K
Forward guidance
This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports
-1.6%
Avg return
Earnings day
-11.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
44%
11 / 25 earnings
Positive
+38.7%
Q3 2022
Best reaction
-45.8%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +2.6% | +4.5% | +21.9% | |
| Q2 2025 | +1.0% | +8.6% | +28.1% | |
| Q1 2025 | +0.0% | -8.3% | +46.2% | |
| Q4 2024 | -0.9% | +0.9% | -6.2% | |
| Q3 2024 | -10.3% | -37.1% | -41.7% | |
| Q2 2024 | -5.8% | +2.5% | -23.3% | |
| Q1 2024 | -45.7% | -50.1% | -51.8% | |
| Q4 2023 | -0.7% | -13.0% | -13.6% | |
| Q3 2023 | +8.2% | — | — | |
| Q2 2023 | -4.8% | — | — | |
| Q1 2023 | -3.5% | — | — | |
| Q4 2022 | -28.4% | — | — | |
| Q3 2022 | +38.7% | — | — | |
| Q2 2022 | +18.7% | — | — | |
| Q1 2022 | +9.7% | — | — | |
| Q4 2021 | +9.2% | — | — | |
| Q3 2021 | -1.9% | — | — | |
| Q2 2021 | -0.4% | — | — | |
| Q1 2021 | -4.0% | — | — | |
| Q4 2020 | +12.0% | — | — | |
| Q3 2020 | -45.8% | — | — | |
| Q2 2020 | +12.3% | — | — | |
| Q1 2020 | +3.7% | — | — | |
| Q4 2019 | +8.7% | — | — | |
| Q3 2019 | -12.3% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro